What is it about?
A new drug-like molecules using a reusable nano-catalyst in a simple, eco-friendly one-step process was developed. One standout compound (compound 4) strongly blocked CDK4, a protein that drives breast cancer growth. It killed breast cancer cells as effectively as standard drugs but showed low toxicity to normal cells. It also stopped cancer cells from dividing and triggered their self-destruction. This makes compound 4 a promising, selective, and sustainable candidate for future breast cancer treatment.
Featured Image
Why is it important?
This work is novel for combining green chemistry with anticancer drug discovery. Using recyclable Mn3O4 nanocatalysts, it synthesizes new triazolopyrimidine derivatives in one pot, then identifies compound 4 as a selective CDK4 inhibitor. It matches doxorubicin's potency against breast cancer cells while sparing normal cells a rare balance of sustainability and therapeutic promise.
Perspectives
This work elegantly bridges green chemistry and oncology. The Mn₃O₄ nanocatalyst enables a sustainable one-pot route to novel triazolopyrimidines, while computational and biological validation converge on compound 4 as a potent, selective CDK4 inhibitor. Its nanomolar-range activity against breast cancer lines, G0/G1 arrest, and low normal-cell toxicity highlight a promising lead for targeted therapy.
Gehan El-Bassyouni
National Research Centre (NRC), Dokki, Cairo, 12622, Egypt
Read the Original
This page is a summary of: Sustainable One‐Pot Synthesis of Novel Triazolopyrimidine Derivatives as Selective CDK4 Inhibitors for Breast Cancer Therapy, Drug Development Research, May 2026, Wiley,
DOI: 10.1002/ddr.70322.
You can read the full text:
Contributors
The following have contributed to this page
